Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Bolt Biotherapeutics (BOLT) FCF Margin (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed FCF Margin for 6 consecutive years, with 286.24% as the latest value for Q4 2025.

  • Quarterly FCF Margin changed N/A to 286.24% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 518.8% through Dec 2025, up 27872.0% year-over-year, with the annual reading at 518.8% for FY2025, 27872.0% up from the prior year.
  • FCF Margin hit 286.24% in Q4 2025 for Bolt Biotherapeutics, up from 452.01% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 286.24% in Q4 2025 to a low of 3354.13% in Q4 2021.
  • Historically, FCF Margin has averaged 1258.91% across 5 years, with a median of 1093.7% in 2025.
  • Biggest five-year swings in FCF Margin: soared 198440bps in 2022 and later tumbled -77608bps in 2025.
  • Year by year, FCF Margin stood at 3354.13% in 2021, then soared by 58bps to 1397.8% in 2022, then surged by 51bps to 680.56% in 2023, then plummeted by -80bps to 1224.36% in 2024, then surged by 77bps to 286.24% in 2025.
  • Business Quant data shows FCF Margin for BOLT at 286.24% in Q4 2025, 452.01% in Q3 2025, and 531.98% in Q2 2025.